Omeros (OMER) Q2 2025 earnings summary

Executive summary

• Net loss for Q2 2025 was $25.4 million ($0.43/share), a significant improvement from $56.0 million ($0.97/share) in Q2 2024, mainly due to lower narsoplimab manufacturing expenses.

• Cash and investments stood at $28.7 million as of June 30, 2025, with an additional $20.6 million raised in July via a direct offering at a 14% premium.

• Debt restructuring reduced 2026 Notes from $97.9 million to $17.1 million, extended maturities to 2029, and eliminated a $20 million prepayment requirement.

• Regulatory progress for narsoplimab includes FDA BLA resubmission with a PDUFA date extended to December 26, 2025, and EMA MAA review with a decision expected mid-2026.

• Ongoing advanced discussions for a potential multi-billion dollar asset/licensing transaction expected to provide upfront cash, debt repayment, and over 12 months of operational runway post-closing.

Financial highlights

• Q2 2025 net loss: $25.4 million ($0.43/share) vs. $56.0 million ($0.97/share) in Q2 2024; six-month net loss was $58.9 million ($1.01/share).

• Cash and investments: $28.7 million at quarter-end, plus $20.6 million raised post-quarter.

• Operating expenses dropped to $32.4 million in Q2 2025 from $59.2 million in Q2 2024.

• Interest expense fell to $15,000 in Q2 2025 from $9.2 million, mainly due to OMIDRIA royalty obligation remeasurement.

• Net income from discontinued operations (OMIDRIA) was $0.5 million in Q2 2025, down from $9.1 million in Q2 2024.

Outlook and guidance

• Q3 2025 operating expenses expected to decrease due to reduced clinical development and cost controls.

• Interest expense (excluding non-cash adjustments) projected at $9.2 million for Q3 2025.

• Ongoing need to raise additional capital; potential asset/licensing transaction could provide significant upfront and milestone payments.

• Preparing for anticipated narsoplimab approval and launch in TA-TMA, with phased onboarding of hematology-experienced sales professionals.

• Multiple value-driving milestones anticipated through 2025 and into 2026, including potential asset transactions.